Two weeks ago,
bluebird bio secured Food and Drug Administration
approval for its gene therapy for sickle cell disease, a significant milestone for the roughly 100,000 people in the U.S. who suffer from the condition.
Two weeks ago,
bluebird bio secured Food and Drug Administration
approval for its gene therapy for sickle cell disease, a significant milestone for the roughly 100,000 people in the U.S. who suffer from the condition.
